Gene polymorphisms associated with heterogeneity and senescence characteristics of sarcopenia in chronic obstructive pulmonary disease.
Fat mass and obesity gene
Gene knockout
Genetic variability
Murine myotubes
Prolonged intermittent hypoxia
Sarcopenia in COPD
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
16
01
2023
received:
23
08
2022
accepted:
22
01
2023
medline:
4
4
2023
pubmed:
2
3
2023
entrez:
1
3
2023
Statut:
ppublish
Résumé
Sarcopenia, or loss of skeletal muscle mass and decreased contractile strength, contributes to morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD). The severity of sarcopenia in COPD is variable, and there are limited data to explain phenotype heterogeneity. Others have shown that COPD patients with sarcopenia have several hallmarks of cellular senescence, a potential mechanism of primary (age-related) sarcopenia. We tested if genetic contributors explain the variability in sarcopenic phenotype and accelerated senescence in COPD. To identify gene variants [single nucleotide polymorphisms (SNPs)] associated with sarcopenia in COPD, we performed a genome-wide association study (GWAS) of fat free mass index (FFMI) in 32 426 non-Hispanic White (NHW) UK Biobank participants with COPD. Several SNPs within the fat mass and obesity-associated (FTO) gene were associated with sarcopenia that were validated in an independent COPDGene cohort (n = 3656). Leucocyte telomere length quantified in the UK Biobank cohort was used as a marker of senescence. Experimental validation was done by genetic depletion of FTO in murine skeletal myotubes exposed to prolonged intermittent hypoxia or chronic hypoxia because hypoxia contributes to sarcopenia in COPD. Molecular biomarkers for senescence were also quantified with FTO depletion in murine myotubes. Multiple SNPs located in the FTO gene were associated with sarcopenia in addition to novel SNPs both within and in proximity to the gene AC090771.2, which transcribes long non-coding RNA (lncRNA). To replicate our findings, we performed a GWAS of FFMI in NHW subjects from COPDGene. The SNP most significantly associated with FFMI was on chromosome (chr) 16, rs1558902A > T in the FTO gene (β = 0.151, SE = 0.021, P = 1.40 × 10 Genetic polymorphisms of FTO and AC090771.2 were associated with sarcopenia in COPD in independent cohorts. Knockdown of FTO in murine myotubes caused a molecular phenotype consistent with senescence that was exacerbated by hypoxia, a common condition in COPD. Genetic variation may interact with hypoxia and contribute to variable severity of sarcopenia and skeletal muscle molecular senescence phenotype in COPD.
Sections du résumé
BACKGROUND
Sarcopenia, or loss of skeletal muscle mass and decreased contractile strength, contributes to morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD). The severity of sarcopenia in COPD is variable, and there are limited data to explain phenotype heterogeneity. Others have shown that COPD patients with sarcopenia have several hallmarks of cellular senescence, a potential mechanism of primary (age-related) sarcopenia. We tested if genetic contributors explain the variability in sarcopenic phenotype and accelerated senescence in COPD.
METHODS
To identify gene variants [single nucleotide polymorphisms (SNPs)] associated with sarcopenia in COPD, we performed a genome-wide association study (GWAS) of fat free mass index (FFMI) in 32 426 non-Hispanic White (NHW) UK Biobank participants with COPD. Several SNPs within the fat mass and obesity-associated (FTO) gene were associated with sarcopenia that were validated in an independent COPDGene cohort (n = 3656). Leucocyte telomere length quantified in the UK Biobank cohort was used as a marker of senescence. Experimental validation was done by genetic depletion of FTO in murine skeletal myotubes exposed to prolonged intermittent hypoxia or chronic hypoxia because hypoxia contributes to sarcopenia in COPD. Molecular biomarkers for senescence were also quantified with FTO depletion in murine myotubes.
RESULTS
Multiple SNPs located in the FTO gene were associated with sarcopenia in addition to novel SNPs both within and in proximity to the gene AC090771.2, which transcribes long non-coding RNA (lncRNA). To replicate our findings, we performed a GWAS of FFMI in NHW subjects from COPDGene. The SNP most significantly associated with FFMI was on chromosome (chr) 16, rs1558902A > T in the FTO gene (β = 0.151, SE = 0.021, P = 1.40 × 10
CONCLUSIONS
Genetic polymorphisms of FTO and AC090771.2 were associated with sarcopenia in COPD in independent cohorts. Knockdown of FTO in murine myotubes caused a molecular phenotype consistent with senescence that was exacerbated by hypoxia, a common condition in COPD. Genetic variation may interact with hypoxia and contribute to variable severity of sarcopenia and skeletal muscle molecular senescence phenotype in COPD.
Identifiants
pubmed: 36856146
doi: 10.1002/jcsm.13198
pmc: PMC10067501
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1083-1095Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM119174
Pays : United States
Organisme : NIH HHS
ID : 5U01DK062470-17S2
Pays : United States
Organisme : NIH HHS
ID : U01 HL089856
Pays : United States
Organisme : NHLBI NIH HHS
ID : R56 HL141744
Pays : United States
Organisme : NIH HHS
ID : R01 HL153460
Pays : United States
Organisme : Howard and Helen Trevey Endowment
Organisme : NIAAA NIH HHS
ID : U01 AA021890
Pays : United States
Organisme : NIH HHS
ID : P50 AA024333
Pays : United States
Organisme : NIH HHS
ID : U01 HL089897
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061732
Pays : United States
Organisme : NIH HHS
ID : R21 AR 071046
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK113196
Pays : United States
Organisme : NIH HHS
ID : K12 HL141952
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA026976
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL156499
Pays : United States
Informations de copyright
© 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Aging Clin Exp Res. 2012 Jun;24(3):213-7
pubmed: 23114548
J Hum Genet. 2018 May;63(5):627-638
pubmed: 29491472
J Cachexia Sarcopenia Muscle. 2023 Apr;14(2):1083-1095
pubmed: 36856146
Nat Commun. 2021 Jan 28;12(1):654
pubmed: 33510174
BMC Genet. 2017 Jan 19;18(1):4
pubmed: 28103813
Aging (Albany NY). 2016 Jan;8(1):3-11
pubmed: 26805432
Am J Respir Cell Mol Biol. 2011 Aug;45(2):304-10
pubmed: 21037115
J Physiol. 2023 Feb;601(3):567-606
pubmed: 36533558
Eur Respir J. 2003 Feb;21(2):347-60
pubmed: 12608452
Biomed Rep. 2021 Apr;14(4):34
pubmed: 33732453
BMC Geriatr. 2018 Dec 12;18(1):308
pubmed: 30541467
Int J Chron Obstruct Pulmon Dis. 2021 Jan 07;16:25-40
pubmed: 33442246
Front Aging Neurosci. 2022 May 23;14:878278
pubmed: 35677200
Nat Biotechnol. 2012 Nov;30(11):1095-106
pubmed: 23138309
Commun Biol. 2020 Oct 23;3(1):608
pubmed: 33097823
Am J Clin Nutr. 2014 May;99(5):999-1005
pubmed: 24572565
Hepatology. 2021 May;73(5):1892-1908
pubmed: 32799332
Am J Hum Genet. 2009 Jul;85(1):106-11
pubmed: 19559399
Cell Death Dis. 2017 Mar 23;8(3):e2702
pubmed: 28333151
Sci Transl Med. 2019 Nov 6;11(517):
pubmed: 31694926
Korean J Fam Med. 2019 Mar;40(2):87-92
pubmed: 30929418
Curr Opin Pulm Med. 2010 Mar;16(2):123-33
pubmed: 20071991
Circulation. 2019 Jan 22;139(4):518-532
pubmed: 29997116
Int J Chron Obstruct Pulmon Dis. 2018 Jun 25;13:1987-1998
pubmed: 29970961
J Nutr. 1997 May;127(5 Suppl):998S-1003S
pubmed: 9164283
Trends Genet. 2022 Feb;38(2):182-193
pubmed: 34294427
Chron Respir Dis. 2018 Aug;15(3):250-257
pubmed: 29186972
PLoS One. 2022 Feb 17;17(2):e0263657
pubmed: 35176055
Int J Mol Sci. 2020 Oct 31;21(21):
pubmed: 33142830
Biochim Biophys Acta. 2014 Oct;1842(10):2039-47
pubmed: 24518103
Medicine (Baltimore). 2020 Dec 11;99(50):e23642
pubmed: 33327343
Mol Cell Biochem. 2021 May;476(5):2171-2179
pubmed: 33548009
Nature. 2009 Apr 16;458(7240):894-8
pubmed: 19234441
Public Health. 2021 Apr;193:101-108
pubmed: 33773322
JCI Insight. 2021 Dec 22;6(24):
pubmed: 34935641
Oncogene. 2021 Aug;40(33):5168-5181
pubmed: 34218271
BMC Med Genet. 2013 Jan 11;14:6
pubmed: 23311614
Nature. 2014 Mar 20;507(7492):371-5
pubmed: 24646999
J Hum Kinet. 2011 Sep;29:151-9
pubmed: 23486361
Eur Respir J. 2017 Dec 14;50(6):
pubmed: 29242259
Korean J Fam Med. 2020 May;41(3):167-174
pubmed: 32456384
Nat Rev Mol Cell Biol. 2018 Mar;19(3):143-157
pubmed: 29138516